Update on Targeted therapies and Immunotherapies in Gastric Cancer

Who will move the needle in gastric and oesophageal cancers - targeted therapies or checkpoint immunoherapies?

January 27, 2016

Will pembrolizumab extend its activity in GI cancers?

Will checkpoint blockade be effective in multiple GI cancers and if so, why?

January 25, 2016

Why didn’t Ipilimumab plus Chemo work in Metastatic Urothelial Cancer?

A trial of gemcitabine plus cisplatin plus ipilimumab in patients with metastatic urothelial cancer failed to meet it's primary endpoint.

January 22, 2016

Potential of a Novel Non-Invasive Liquid Biopsy Prostate Cancer Biomarker

A novel non-invasive liquid biopsy may offer a potential novel biomarker that will help in sequencing prostate cancer drugs.

January 21, 2016

New combinations and targets in advanced prostate cancer

How do we overcome resistance to Zytiga? There are some encouraging developments in this area to report.

January 20, 2016

A New Race to Market in Advanced Prostate Cancer

Two biotech companies are in a race to market for a novel target in advanced prostate cancer.

January 19, 2016